Literature DB >> 17554493

Long-term infliximab treatment for Behçet's disease.

Mitsuko Takamoto, Toshikatsu Kaburaki, Jiro Numaga, Yujiro Fujino, Hidetoshi Kawashima.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17554493     DOI： 10.1007/s10384-006-0424-z

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN： 0021-5155            Impact factor:   2.447


× No keyword cloud information.
  5 in total

1.  Anti-TNF-alpha therapy for sight threatening uveitis.

Authors:  E W Lindstedt; G S Baarsma; R W A M Kuijpers; P M van Hagen
Journal:  Br J Ophthalmol       Date:  2005-05       Impact factor: 4.638

2.  Effect of infliximab on sight-threatening panuveitis in Behçet's disease.

Authors:  P P Sfikakis; P G Theodossiadis; C G Katsiari; P Kaklamanis; N N Markomichelakis
Journal:  Lancet       Date:  2001-07-28       Impact factor: 79.321

3.  Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial.

Authors:  Ilknur Tugal-Tutkun; Abdulbaki Mudun; Meri Urgancioglu; Sevil Kamali; Esen Kasapoglu; Murat Inanc; Ahmet Gül
Journal:  Arthritis Rheum       Date:  2005-08

4.  Infliximab in the treatment of refractory posterior uveitis.

Authors:  Annie Joseph; Dev Raj; Harminder S Dua; Pauline T Powell; Peter C Lanyon; Richard J Powell
Journal:  Ophthalmology       Date:  2003-07       Impact factor: 12.079

5.  Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis.

Authors:  Shigeaki Ohno; Satoshi Nakamura; Sadao Hori; Machiko Shimakawa; Hidetoshi Kawashima; Manabu Mochizuki; Sunao Sugita; Satoki Ueno; Kazuyuki Yoshizaki; Goro Inaba
Journal:  J Rheumatol       Date:  2004-07       Impact factor: 4.666
  5 in total
  7 in total

1.  Clinical background comparison of patients with and without ocular inflammatory attacks after initiation of infliximab therapy.

Authors:  Atsushi Yoshida; Toshikatsu Kaburaki; Kimiko Okinaga; Mitsuko Takamoto; Hidetoshi Kawashima; Yujiro Fujino
Journal:  Jpn J Ophthalmol       Date:  2012-10-02       Impact factor: 2.447

Review 2.  Update on the therapy of Behçet disease.

Authors:  Zeinab Saleh; Thurayya Arayssi
Journal:  Ther Adv Chronic Dis       Date:  2014-05       Impact factor: 5.091

Review 3.  Cutting-edge issues in autoimmune uveitis.

Authors:  Roger A Levy; Francisco Assis de Andrade; Ivan Foeldvari
Journal:  Clin Rev Allergy Immunol       Date:  2011-10       Impact factor: 8.667

4.  Ocular inflammation in Behçet disease: incidence of ocular complications and of loss of visual acuity.

Authors:  R Oktay Kaçmaz; John H Kempen; Craig Newcomb; Sapna Gangaputra; Ebenezer Daniel; Grace A Levy-Clarke; Robert B Nussenblatt; James T Rosenbaum; Eric B Suhler; Jennifer E Thorne; Douglas A Jabs; C Stephen Foster
Journal:  Am J Ophthalmol       Date:  2008-08-16       Impact factor: 5.258

5.  Use of biologic agents in ocular manifestations of rheumatic disease.

Authors:  Courtney L Kraus; Susan M Culican
Journal:  Int J Rheumatol       Date:  2011-12-15

6.  Efficacy of infliximab in refractory Behçet's disease-associated and idiopathic posterior segment uveitis: a prospective, follow-up study of 50 patients.

Authors:  Fabrizio Cantini; Laura Niccoli; Carlotta Nannini; Olga Kaloudi; Emanuele Cassarà; Massimo Susini; Ivo Lenzetti
Journal:  Biologics       Date:  2011-12-29

7.  Behçet's disease physiopathology: a contemporary review.

Authors:  Mohamad J Zeidan; David Saadoun; Marlene Garrido; David Klatzmann; Adrien Six; Patrice Cacoub
Journal:  Auto Immun Highlights       Date:  2016-02-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.